Infections of the central nervous system and strokes, primarily focusing on tuberculous meningoencephalitis and acute ischemic stroke.
Conditions
Interventions
Case Group:None
Control group:None
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Tuberculosis Group (1) Meets the diagnostic criteria of the "2019 Chinese Guidelines for Diagnosis and Treatment of Central Nervous System Tuberculosis"; (2) Meets the diagnostic criteria of the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023"; (3) Age 14–85 years, no gender restriction; (4) Hospitalization duration 7–30 days; (5) Complete medical records. 2. Viral Group (1) Meets the clinical diagnostic criteria for viral meningitis, referring to "Adult Aseptic Meningitis"; (2) Meets the diagnostic criteria of the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023"; (3) Age 14–85 years, no gender restriction; (4) Hospitalization duration 7–30 days; (5) Complete medical records. 3. Control Group (1) For the tuberculosis group, meets the diagnostic criteria of the "2019 Chinese Guidelines for Diagnosis and Treatment of Central Nervous System Tuberculosis"; (2) For the viral group, meets the clinical diagnostic criteria for viral meningitis, referring to "Adult Aseptic Meningitis"; (3) Age 14–85 years, matched by hospitalization period, age, and sex with patients having tuberculous or viral meningitis-associated cerebral infarction; (4) Complete medical records.
Exclusion criteria
Exclusion criteria: 1. Tuberculosis Group (1) Exclude history of ischemic stroke, traumatic brain injury, brain tumor, or cerebral hemorrhage; (2) Exclude fungal meningitis, viral meningitis, and other bacterial meningitis; (3) Suspected mixed infection with two or more pathogens; (4) Comorbid malignancy, rheumatic immune diseases, hematologic disorders, or severe organ dysfunction; (5) Use of glucocorticoids and immunosuppressants within the past 3 months; (6) HIV and Treponema pallidum infection; (7) Contraindications to magnetic resonance imaging (MRI); (8) Incomplete medical records. 2. Viral Group (1) Exclude history of ischemic stroke, traumatic brain injury, brain tumor, or cerebral hemorrhage; (2) Exclude fungal meningitis and bacterial meningitis; (3) Suspected mixed infection with two or more pathogens; (4) Comorbid malignancy, rheumatic immune diseases, hematologic disorders, or severe organ dysfunction; (5) Use of glucocorticoids and immunosuppressants within the past 3 months; (6) HIV and Treponema pallidum infection; (7) Contraindications to magnetic resonance imaging (MRI); (8) Incomplete medical records. 3. Control Group (1) Exclude history of ischemic stroke, traumatic brain injury, brain tumor, or cerebral hemorrhage; (2) Exclude central nervous system infections other than tuberculous or viral meningitis; (3) Suspected mixed infection with two or more pathogens; (4) Comorbid malignancy, rheumatic immune diseases, hematologic disorders, or severe organ dysfunction; (5) Use of glucocorticoids and immunosuppressants within the past 3 months; (6) HIV and Treponema pallidum infection; (7) Contraindications to magnetic resonance imaging (MRI); (8) Incomplete medical records.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke incidence rate;Functional outcome at 90 days (mRS >= 3);In-hospital mortality after stroke; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in neurological function scores;Correlation between biomarkers and stroke risk;Imaging changes;Hospital length of stay and cost; | — |
Countries
China
Contacts
Public ContactZheng Ying
First Affiliated Hospital of Kunming Medical University
Outcome results
None listed